{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:43:57Z","timestamp":1790286237877,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU 303, 2167\/1, RTG1727"],"award-info":[{"award-number":["CRU 303, 2167\/1, RTG1727"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"publisher","award":["CS06\u20102019"],"award-info":[{"award-number":["CS06\u20102019"]}],"id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rituximab induces a rapid remission in most patients with pemphigus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Our aim was to assess the long\u2010term efficacy of rituximab in this disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We conducted a retrospective study of 59 patients with pemphigus treated with rituximab and observed over a median period of 104\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The rate of complete remission off therapy (CRoff) after the first rituximab cycle was 39%, increasing to 61% with additional rituximab courses. Long\u2010term CRoff was achieved in 27% of patients. The recurrence rate after the first rituximab cycle was 63%, decreasing to approximately 40% with subsequent rituximab cycles. Median time to relapse after the first and subsequent rituximab cycles was 25\u00a0months. Renewed rituximab therapy reinduced complete remission in 94% of cases. Baseline anti\u2010desmoglein antibody levels of \u2264250\u00a0U\/mL were significantly associated with the outcome of CRoff. In paired serum samples obtained before the first and six months after the last rituximab therapy, significant reductions of desmoglein\u2010specific autoantibodies were observed. Patients relapsing after a complete remission induced by the first rituximab cycle were more likely to achieve CRoff than patients relapsing after a less favourable outcome and non\u2010responders. There was no significant difference in age, sex, pemphigus subtype, rituximab dosing and disease duration between patients achieving CRoff and those not meeting this end point.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Lower desmoglein\u2010specific antibody levels at baseline were predictive of CRoff. In patients receiving multiple rituximab cycles, complete remission after the first cycle was associated with a favourable long\u2010term outcome. Repeated rituximab courses were highly effective for relapsed disease and improved the overall outcome.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.16561","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T05:26:57Z","timestamp":1588656417000},"page":"2884-2889","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long\u2010term outcomes of rituximab therapy in pemphigus"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-2682","authenticated-orcid":false,"given":"I.","family":"Shimanovich","sequence":"first","affiliation":[{"name":"Department of Dermatology University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Baumann","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of L\u00fcbeck L\u00fcbeck Germany"},{"name":"L\u00fcbeck Institute for Experimental Dermatology (LIED) University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zillikens","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Hammers","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of L\u00fcbeck L\u00fcbeck Germany"},{"name":"L\u00fcbeck Institute for Experimental Dermatology (LIED) University of L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7"},{"key":"e_1_2_5_3_1","first-page":"269","article-title":"Anti\u2010CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma\u2010associated paraneoplastic pemphigus","volume":"137","author":"Borradori L","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2116"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3236"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.11.007"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.12.019"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13103"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.11.024"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14546"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_848_17"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13757"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12763"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2010.01069.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1666"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1522"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.172"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09680.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.032"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T19:23:53Z","timestamp":1693423433000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/jdv.16561"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16561","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"2020-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}